Dauletbaev N, Herscovitch K, Das M, Chen H, Bernier J, Matouk E, Bérubé J, Rousseau S, Lands L C
Translational Research in Respiratory Diseases, The Research Institute of McGill University Health Centre, Montreal, QC, Canada.
Division of Respiratory Medicine, Montreal Chest Institute, Montreal, QC, Canada.
Br J Pharmacol. 2015 Oct;172(19):4757-71. doi: 10.1111/bph.13249.
There is current interest in vitamin D as a potential anti-inflammatory treatment for chronic inflammatory lung disease, including cystic fibrosis (CF). Vitamin D transcriptionally up-regulates the anti-inflammatory gene DUSP1, which partly controls production of the inflammatory chemokine IL-8. IL-8 is overabundant in CF airways, potentially due to hyperinflammatory responses of CF macrophages. We tested the ability of vitamin D metabolites to down-regulate IL-8 production in CF macrophages.
CF and healthy monocyte-derived macrophages (MDM) were treated with two vitamin D metabolites, 25-hydroxyvitamin D3 (25OHD3 ) and 1,25-dihydroxyvitamin D3 (1,25(OH)2 D3 ), or paricalcitol, synthetic analogue of 1,25(OH)2 D3 . 25OHD3 was tested at doses of 25-150 nM, whereas 1,25(OH)2 D3 and paricalcitol at doses of up to 100 nM. IL-8 was stimulated by bacterial virulence factors. As potential anti-inflammatory mechanism of vitamin D metabolites, we assessed up-regulation of DUSP1.
MDM from patients with CF and some healthy donors showed excessive production of stimulated IL-8, highlighting their hyperinflammatory phenotype. Vitamin D metabolites down-regulated stimulated IL-8 only in those hyperinflammatory MDM, and only when used at high doses (>100 nM for 25OHD3 , or >1 nM for 1,25(OH)2 D3 and paricalcitol). The magnitude of IL-8 down-regulation by vitamin D metabolites or paricalcitol was moderate (∼30% vs. >70% by low-dose dexamethasone). Transcriptional up-regulation of DUSP1 by vitamin D metabolites was seen in all tested MDM, regardless of IL-8 down-regulation.
Vitamin D metabolites and their analogues moderately down-regulate IL-8 in hyperinflammatory macrophages, including those from CF. This down-regulation appears to go through DUSP1-independent mechanisms.
目前,维生素D作为慢性炎症性肺病(包括囊性纤维化,CF)的一种潜在抗炎治疗手段受到关注。维生素D可通过转录上调抗炎基因DUSP1,该基因部分控制炎症趋化因子IL - 8的产生。CF气道中IL - 8过量,这可能是由于CF巨噬细胞的过度炎症反应所致。我们测试了维生素D代谢产物下调CF巨噬细胞中IL - 8产生的能力。
用两种维生素D代谢产物,即25 - 羟基维生素D3(25OHD3)和1,25 - 二羟基维生素D3(1,25(OH)2D3),或1,25(OH)2D3的合成类似物帕立骨化醇处理CF和健康的单核细胞衍生巨噬细胞(MDM)。25OHD3的测试剂量为25 - 150 nM,而1,25(OH)2D3和帕立骨化醇的测试剂量高达100 nM。用细菌毒力因子刺激IL - 8产生。作为维生素D代谢产物潜在的抗炎机制,我们评估了DUSP1的上调情况。
CF患者和一些健康供体的MDM显示出受刺激后IL - 8的过量产生,突出了它们的过度炎症表型。维生素D代谢产物仅在那些过度炎症的MDM中下调受刺激后的IL - 8,并且仅在高剂量使用时(25OHD3 > 100 nM,或1,25(OH)2D3和帕立骨化醇 > 1 nM)才会出现这种情况。维生素D代谢产物或帕立骨化醇对IL - 8的下调幅度适中(约30%,而低剂量地塞米松的下调幅度>70%)。无论IL - 8是否下调,在所有测试的MDM中均可见维生素D代谢产物对DUSP1的转录上调。
维生素D代谢产物及其类似物可适度下调过度炎症巨噬细胞(包括CF患者的巨噬细胞)中的IL - 8。这种下调似乎通过不依赖DUSP1的机制实现。